R&D Trends

Edison, Dainippon Sumitomo to develop orphan mitochondrial and adult CNS disease drugs

Friday, March 29, 2013 01:09 PM

Specialty pharmaceutical company Edison Pharmaceuticals has entered into a R&D and commercialization agreement with Dainippon Sumitomo Pharma, a Japanese pharmaceutical company, for the development of EPI-743 and EPI-589 in Japan.

More... »

GSK, Texas A&M to establish influenza vaccine facility in Texas

Friday, March 29, 2013 11:20 AM

The U.S. Department of Health and Human Services (DHHS) has approved GlaxoSmithKline’s (GSK) and The Texas A&M University System’s proposal to establish a $91 million influenza-vaccines manufacturing facility as the anchor of the Center for Innovation in Advanced Development and Manufacturing (CIADM) in Bryan-College Station, Texas.

More... »

BioDelivery Sciences acquires topical clonidine gel for painful diabetic neuropathy

Wednesday, March 27, 2013 11:53 AM

BioDelivery Sciences International (BDSI) has entered into a worldwide licensing agreement with privately held Arcion Therapeutics, where BDSI will develop and commercialize topical clonidine gel (formerly ARC4558) for the treatment of painful diabetic neuropathy (PDN) and potentially other indications. 

More... »

Lundbeck, Otsuka expand alliance, plan to development Lu AE58054 for Alzheimer's

Wednesday, March 27, 2013 11:24 AM

Global pharmaceutical company H. Lundbeck and global healthcare company Otsuka Pharmaceutical have formed a license and development agreement for Lu AE58054, a selective 5HT6 receptor antagonist currently in development for the treatment of Alzheimer's disease.

More... »

PrimeraDx, Quest Diagnostics to develop companion diagnostics

Wednesday, March 27, 2013 10:26 AM

PrimeraDx, a molecular diagnostics company, has formed a non-exclusive diagnostics co-development agreement with Quest Diagnostics, a diagnostics information services company. The intent of the collaboration is to co-develop and commercialize molecular diagnostic products and services with a focus on supporting clinical development of targeted therapeutics for drug developers.

More... »

Spinifex receives $1.5M in R&D tax incentive relating to pain research

Wednesday, March 27, 2013 09:28 AM

Spinifex Pharmaceuticals, an Australian pain drug development company, has received an approximately $1.5 million R&D tax incentives cash refund for research activities relating to the discovery of new drugs for the treatment and management of pain.

More... »

Survey underscores importance of patient education and engagement in personalized medicine

Monday, March 25, 2013 02:17 PM

Nearly two out of three people in four major European countries have no awareness of personalized medicine—despite the fact that this evolving discipline has vast implications for Europe's healthcare issues and Europeans' personal health.

More... »

Sanofi, Transgene form long-term collaboration for production of immunotherapy treatments

Monday, March 25, 2013 12:24 PM

Global healthcare company Sanofi and biopharmaceutical company Transgene have signed a collaboration agreement for the creation of a new state-of-the-art industrial platform dedicated to the production of immunotherapy products including Transgene's therapeutic products.

More... »

Third Rock Ventures raises $516M Fund III

Monday, March 25, 2013 11:56 AM

Third Rock Ventures, a venture capital firm, announced the final closing of Fund III, raising $516 million in an oversubscribed fund. With Fund III, Third Rock will continue to execute on its strategy of launching, building and supporting transformative healthcare companies.

More... »

Astellas inks two new dengue virus research collaborations

Monday, March 25, 2013 10:30 AM

Global pharmaceutical company Astellas Pharma has signed collaborative research agreements with both the Nagasaki University and the Tokyo Institute of Technology, both located in Japan, regarding the dengue virus.

More... »